

# Upendra A Argikar

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2844706/publications.pdf>

Version: 2024-02-01

36  
papers

784  
citations

567281

15  
h-index

526287

27  
g-index

37  
all docs

37  
docs citations

37  
times ranked

975  
citing authors

#	ARTICLE	IF	CITATIONS
1	Biotransformation novel advances â€“ 2021 year in review. Drug Metabolism Reviews, 2022, 54, 207-245.	3.6	3
2	Understanding metabolism related differences in ocular efficacy of MGV354. Xenobiotica, 2021, 51, 5-14.	1.1	2
3	Case Study 2: Practical Analytical Considerations for Conducting In Vitro Enzyme Kinetic Studies. Methods in Molecular Biology, 2021, 2342, 643-652.	0.9	0
4	Enzyme Kinetics of Uridine Diphosphate Glucuronosyltransferases (UGTs). Methods in Molecular Biology, 2021, 2342, 301-338.	0.9	8
5	Novel advances in biotransformation and bioactivation research â€“ 2020 year in review. Drug Metabolism Reviews, 2021, 53, 384-433.	3.6	4
6	Comparative Proteomics Analysis of the Postmitochondrial Supernatant Fraction of Human Lens-Free Whole Eye and Liver. Drug Metabolism and Disposition, 2021, 49, 592-600.	3.3	5
7	Discovery of 4-((2 <i>S</i> ,4 <i>S</i> )-4-Ethoxy-1-((5-methoxy-7-methyl-1 <i>H</i> -indol-4-yl)methyl)piperidin-2-yl)benzoic Acid (LNPO23), a Factor B Inhibitor Specifically Designed To Be Applicable to Treating a Diverse Array of Complement Mediated Diseases. Journal of Medicinal Chemistry, 2020, 63, 5697-5722.	6.4	25
8	Design, Synthesis, and Preclinical Characterization of Selective Factor D Inhibitors Targeting the Alternative Complement Pathway. Journal of Medicinal Chemistry, 2019, 62, 4656-4668.	6.4	16
9	Small-molecule factor B inhibitor for the treatment of complement-mediated diseases. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 7926-7931.	7.1	116
10	UDP-Glucuronosyltransferases. , 2019, , 109-159.		5
11	New Perspectives on Acyl Glucuronide Risk Assessment in Drug Discovery: Investigation of In vitro Stability, In situ Reactivity, and Bioactivation. Drug Metabolism Letters, 2018, 12, 84-92.	0.8	12
12	The mesentery: an ADME perspective on a â€“newâ€™ organ. Drug Metabolism Reviews, 2018, 50, 398-405.	3.6	16
13	Models and Approaches Describing the Metabolism, Transport, and Toxicity of Drugs Administered by the Ocular Route. Drug Metabolism and Disposition, 2018, 46, 1670-1683.	3.3	16
14	Investigation of Ocular Bioactivation Potential and the Role of Cytochrome P450 2D Enzymes in Rat. Drug Metabolism Letters, 2018, 11, 102-110.	0.8	2
15	InÂvitro ocular metabolism and bioactivation of ketoconazole in rat, rabbit and human. Drug Metabolism and Pharmacokinetics, 2017, 32, 121-126.	2.2	13
16	Implications for Metabolite Quantification by Mass Spectrometry in the Absence of Authentic Standards. Drug Metabolism and Disposition, 2017, 45, 492-496.	3.3	23
17	Ocular non-P450 oxidative, reductive, hydrolytic, and conjugative drug metabolizing enzymes. Drug Metabolism Reviews, 2017, 49, 372-394.	3.6	20
18	Discovery of Highly Potent and Selective Small-Molecule Reversible Factor D Inhibitors Demonstrating Alternative Complement Pathway Inhibition <i>in Vivo</i> . Journal of Medicinal Chemistry, 2017, 60, 5717-5735.	6.4	27

#	ARTICLE	IF	CITATIONS
19	Do We Need to Study Metabolism and Distribution in the Eye: Why, When, and Are We There Yet?. Journal of Pharmaceutical Sciences, 2017, 106, 2276-2281.	3.3	20
20	Optimization of Allosteric With-No-Lysine (WNK) Kinase Inhibitors and Efficacy in Rodent Hypertension Models. Journal of Medicinal Chemistry, 2017, 60, 7099-7107.	6.4	27
21	Ocular Metabolism of Levobunolol: Historic and Emerging Metabolic Pathways. Drug Metabolism and Disposition, 2016, 44, 1304-1312.	3.3	13
22	Challenges and Opportunities with Non-CYP Enzymes Aldehyde Oxidase, Carboxylesterase, and UDP-Glucuronosyltransferase: Focus on Reaction Phenotyping and Prediction of Human Clearance. AAPS Journal, 2016, 18, 1391-1405.	4.4	79
23	Compound Property Optimization in Drug Discovery Using Quantitative Surface Sampling Micro Liquid Chromatography with Tandem Mass Spectrometry. Analytical Chemistry, 2016, 88, 11813-11820.	6.5	11
24	An in vitro approach to investigate ocular metabolism of a topical, selective $\beta_1$ -adrenergic blocking agent, betaxolol. Xenobiotica, 2015, 45, 396-405.	1.1	10
25	Identification of saturated and unsaturated fatty acids released during microsomal incubations. Xenobiotica, 2014, 44, 687-695.	1.1	9
26	Case Study 2. Practical Analytical Considerations for Conducting In Vitro Enzyme Kinetic Studies. Methods in Molecular Biology, 2014, 1113, 431-439.	0.9	2
27	Metabolism of Bromopride in Mouse, Rat, Rabbit, Dog, Monkey, and Human Hepatocytes. Drug Metabolism and Pharmacokinetics, 2013, 28, 453-461.	2.2	11
28	Unusual Glucuronides. Drug Metabolism and Disposition, 2012, 40, 1239-1251.	3.3	33
29	An experimental approach to enhance precursor ion fragmentation for metabolite identification studies: application of dual collision cells in an orbital trap. Rapid Communications in Mass Spectrometry, 2011, 25, 1356-1362.	1.5	28
30	Evaluation of Pharmaceutical Excipients as Cosolvents in 4-Methyl Umbelliferone Glucuronidation in Human Liver Microsomes: Applications for Compounds with Low Solubility. Drug Metabolism and Pharmacokinetics, 2011, 26, 102-106.	2.2	10
31	Identification of a Novel N-Carbamoyl Glucuronide: In Vitro, In Vivo, and Mechanistic Studies. Drug Metabolism and Disposition, 2010, 38, 361-367.	3.3	28
32	Identification of Novel Metoclopramide Metabolites in Humans: In Vitro and In Vivo Studies. Drug Metabolism and Disposition, 2010, 38, 1295-1307.	3.3	24
33	Effect of Aging on Glucuronidation of Valproic Acid in Human Liver Microsomes and the Role of UDP-Glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10. Drug Metabolism and Disposition, 2009, 37, 229-236.	3.3	114
34	Update on tools for evaluation of uridine diphosphoglucuronosyltransferase polymorphisms. Expert Opinion on Drug Metabolism and Toxicology, 2008, 4, 879-894.	3.3	22
35	Paradoxical urinary phenytoin metabolite (S)/(R) ratios in CYP2C19*1/*2 patients. Epilepsy Research, 2006, 71, 54-63.	1.6	23
36	Conjugative Metabolism of Drugs. , 0, , 37-88.		7